{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:14:08Z","timestamp":1792552448649,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"40","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS117926"],"award-info":[{"award-number":["NS117926"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2024,9,27]]},"DOI":"10.1038\/s41388-024-03144-8","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T04:02:09Z","timestamp":1724904129000},"page":"2995-3002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis"],"prefix":"10.1038","volume":"43","author":[{"given":"Maria A.","family":"Gonz\u00e1lez-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Troutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Duckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6980-9065","authenticated-orcid":false,"given":"Michael S.","family":"Kareta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-346X","authenticated-orcid":false,"given":"Joseph L.","family":"Kissil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"3144_CR1","volume":"3","author":"Y Ren","year":"2021","unstructured":"Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma. Neurooncol Adv. 2021;3:vdaa153.","journal-title":"Neurooncol Adv"},{"key":"3144_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2022.06.003","volume":"134","author":"S Acar","year":"2022","unstructured":"Acar S, Nieblas-Bedolla E, Armstrong AE, Hirbe AC. A systematic review of recent and ongoing clinical trials in patients with the neurofibromatoses. Pediatr Neurol. 2022;134:1\u20136.","journal-title":"Pediatr Neurol"},{"key":"3144_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.otc.2023.02.013","volume":"56","author":"DB Welling","year":"2023","unstructured":"Welling DB. Targeted therapies in the treatment of vestibular schwannomas: current state and new horizons. Otolaryngol Clin North Am. 2023;56:543\u201356.","journal-title":"Otolaryngol Clin North Am"},{"key":"3144_CR4","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1016\/j.febslet.2014.04.001","volume":"588","author":"J Cooper","year":"2014","unstructured":"Cooper J, Giancotti FG. Molecular insights into NF2\/Merlin tumor suppressor function. FEBS Lett. 2014;588:2743\u201352.","journal-title":"FEBS Lett"},{"key":"3144_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41568-023-00579-1","volume":"23","author":"JM Franklin","year":"2023","unstructured":"Franklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat Rev Cancer. 2023;23:512\u201325.","journal-title":"Nat Rev Cancer"},{"key":"3144_CR6","first-page":"9","volume":"4","author":"S Piccolo","year":"2023","unstructured":"Piccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023;4:9\u201326.","journal-title":"Nat Cancer"},{"key":"3144_CR7","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-15-1144","volume":"76","author":"W Guerrant","year":"2016","unstructured":"Guerrant W, Kota S, Troutman S, Mandati V, Fallahi M, Stemmer-Rachamimov A, et al. YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX2-EGFR signaling axis. Cancer Res. 2016;76:3507\u201319.","journal-title":"Cancer Res"},{"key":"3144_CR8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/brain\/awac342","volume":"146","author":"L Laraba","year":"2023","unstructured":"Laraba L, Hillson L, de Guibert JG, Hewitt A, Jaques MR, Tang TT, et al. Inhibition of YAP\/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma. Brain. 2023;146:1697\u2013713.","journal-title":"Brain"},{"key":"3144_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.15698\/cst2021.11.258","volume":"5","author":"G Battilana","year":"2021","unstructured":"Battilana G, Zanconato F, Piccolo S. Mechanisms of YAP\/TAZ transcriptional control. Cell Stress. 2021;5:167\u201372.","journal-title":"Cell Stress"},{"key":"3144_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","volume":"24","author":"F Zanconato","year":"2018","unstructured":"Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A, et al. Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4. Nat Med. 2018;24:1599\u2013610.","journal-title":"Nat Med"},{"key":"3144_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1101\/sqb.2016.81.030908","volume":"81","author":"S Shu","year":"2016","unstructured":"Shu S, Polyak K. BET bromodomain proteins as cancer therapeutic targets. Cold Spring Harb Symp Quant Biol. 2016;81:123\u20139.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"3144_CR12","volume":"4","author":"J Doherty","year":"2022","unstructured":"Doherty J, Mandati V, Gonzalez Rodriguez MA, Troutman S, Shepard A, Harbaugh D, et al. Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2. Neurooncol Adv. 2022;4:vdac072.","journal-title":"Neurooncol Adv"},{"key":"3144_CR13","doi-asserted-by":"publisher","first-page":"54515","DOI":"10.18632\/oncotarget.10248","volume":"7","author":"S Troutman","year":"2016","unstructured":"Troutman S, Moleirinho S, Kota S, Nettles K, Fallahi M, Johnson GL, et al. Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1. Oncotarget. 2016;7:54515\u201325.","journal-title":"Oncotarget"},{"key":"3144_CR14","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68.","journal-title":"Sci Transl Med"},{"key":"3144_CR15","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006;25:5960\u20138.","journal-title":"Oncogene"},{"key":"3144_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"H Yoon","year":"2015","unstructured":"Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2015;63:114\u201328.","journal-title":"J Histochem Cytochem"},{"key":"3144_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s13402-020-00537-1","volume":"43","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Xu B, Shi J, Li J, Lu X, Xu L, et al. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol (Dordr). 2020;43:1049\u201366.","journal-title":"Cell Oncol (Dordr)"},{"key":"3144_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3389\/fcell.2020.00652","volume":"8","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Cheng K, Xu B, Shi J, Qiang J, Shi S, et al. Epigenetic input dictates the threshold of targeting of the integrin-dependent pathway in non-small cell lung cancer. Front Cell Dev Biol. 2020;8:652.","journal-title":"Front Cell Dev Biol"},{"key":"3144_CR19","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1093\/bioinformatics\/btz091","volume":"35","author":"D Du","year":"2019","unstructured":"Du D, Chang CH, Wang Y, Tong P, Chan WK, Chiu Y, et al. Response envelope analysis for quantitative evaluation of drug combinations. Bioinformatics. 2019;35:3761\u201370.","journal-title":"Bioinformatics"},{"key":"3144_CR20","doi-asserted-by":"publisher","first-page":"29105","DOI":"10.1074\/jbc.M113.510933","volume":"288","author":"S Licciulli","year":"2013","unstructured":"Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem. 2013;288:29105\u201314.","journal-title":"J Biol Chem"},{"key":"3144_CR21","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, et al. Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J Clin Oncol. 2019;37:3446\u201354.","journal-title":"J Clin Oncol"},{"key":"3144_CR22","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med. 2022;24:1967\u201377.","journal-title":"Genet Med"},{"key":"3144_CR23","doi-asserted-by":"publisher","first-page":"e141514","DOI":"10.1172\/jci.insight.141514","volume":"5","author":"Z Chen","year":"2020","unstructured":"Chen Z, Li S, Mo J, Hawley E, Wang Y, He Y, et al. Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS\/MAPK signaling. JCI Insight. 2020;5:e141514.","journal-title":"JCI Insight"},{"key":"3144_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-015-0228-4","volume":"34","author":"F Megiorni","year":"2015","unstructured":"Megiorni F, McDowell HP, Camero S, Mannarino O, Ceccarelli S, Paiano M, et al. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition. J Exp Clin Cancer Res. 2015;34:112.","journal-title":"J Exp Clin Cancer Res"},{"key":"3144_CR25","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910659","volume":"11","author":"Y Yan","year":"2019","unstructured":"Yan Y, Ma J, Wang D, Lin D, Pang X, Wang S, et al. The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019;11:e10659.","journal-title":"EMBO Mol Med"},{"key":"3144_CR26","doi-asserted-by":"publisher","first-page":"237ra68","DOI":"10.1126\/scitranslmed.3008639","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6:237ra68\u2013ra68.","journal-title":"Sci Transl Med"},{"key":"3144_CR27","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/0008-5472.CAN-19-2415","volume":"80","author":"S Hoxha","year":"2020","unstructured":"Hoxha S, Shepard A, Troutman A, Diao H, Doherty JR, Janiszewska M, et al. YAP-mediated recruitment of YY1 and EZH2 represses transcription of key cell cycle regulators. Cancer Res. 2020;80:2512\u201322.","journal-title":"Cancer Res"},{"key":"3144_CR28","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/bioinformatics\/btaa102","volume":"36","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2020;36:2645.","journal-title":"Bioinformatics"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03144-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:03:13Z","timestamp":1727427793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-024-03144-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":28,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2024,9,27]]}},"alternative-id":["3144"],"URL":"https:\/\/doi.org\/10.1038\/s41388-024-03144-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest exists. JLK serves as a member of the Scientific Advisory Board for Mulberry Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that all methods were performed in accordance with all relevant guidelines and regulations. All animal experiments complied with NIH guidelines and were approved by the Moffitt Cancer Center IACUC under protocol IS00008425. As this study did not include any patient material there was no need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}